Insights - Iovance (IOVA) is nearing $50/share and touching new 52-week highs with each passing day. Remember, just over two months ago, IOVA was trading at $26/share … Continue Reading
Premium: Read NowInsights - The winner of ASH 2020, the annual blood disease conference, is Fate Therapeutics (FATE). FATE stock is up >30% this morning to a $7B valuation … Continue Reading
Premium: Read NowInsights - Futures are up 1% this morning on news of Moderna’s (MRNA) COVID-19 vaccine showing 94.5% efficacy in their Phase 3. Last week Pfizer reported >90% efficacy for … Continue Reading
Read NowInsights - Aerpio (ARPO) released their Q3 earnings and business update yesterday. The company remains on track to report Phase 2 data in glaucoma in “December or early in … Continue Reading
Premium: Read NowInsights - Pfizer (PFE) and BioNTech (BTNX) revealed that their COVID-19 vaccine was >90% effective in preventing the virus, compared to patients receiving placebo. This is a … Continue Reading
Read NowInsights - Tomorrow, Friday November 6, the FDA will hold an ADCOM for Biogen’s (BIIB) aducanumab. Aducanumab is a beta-amyloid drug for Alzheimer’s Disease that can receive … Continue Reading
Premium: Read NowInsights - Affimed’s (AFMD) ASH abstract for AFM13 was released today. The abstract (see here) covers AFM13 Phase 1 in relapsed/refractory CD30+ lymphoma patients. Affimed refers to this … Continue Reading
Premium: Read Now
